Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | TACR3 | P29371 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16941896 | 0.84 | NPC1 (0.52) | NPC1RAB9ATACR3POLBMGLL | |
| SCHEMBL27449720 | 0.81 | NPC1 (0.49) | NPC1RAB9ATACR3POLBMGLL | |
| SCHEMBL397013 | 0.81 | NPC1 (0.45) | NPC1RAB9ATACR3POLBKMT2A | |
| SCHEMBL3105408 | 0.80 | RAB9A (0.60) | NPC1RAB9ATACR3POLBKMT2A | |
| SCHEMBL31480591 | 0.76 | NPC1 (0.54) | NPC1RAB9ATACR3POLBKMT2A | |
| SCHEMBL395760 | 0.76 | TACR3 (0.46) | NPC1RAB9ATACR3POLBKMT2A | |
| SCHEMBL27401772 | 0.74 | KMT2A (0.53) | NPC1RAB9ATACR3POLBKMT2A | |
| SCHEMBL15850141 | 0.74 | HCAR2 (0.45) | POLBMAOB | |
| SCHEMBL31480389 | 0.74 | NPC1 (0.55) | NPC1RAB9ATACR3POLBMGLL | |
| SCHEMBL17420472 | 0.72 | NPC1 (0.68) | NPC1RAB9APOLBMGLLMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150328227-A1 | ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2015-11-19 | — | — | US | disclosed |
| US-20150328227-A1 | ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2015-11-19 | — | — | US | disclosed |
| US-9145393-B2 | Arylpyridinone ITK inhibitors for treating inflammation and cancer | CONFLUENCE LIFE SCIENCES, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-9145393-B2 | Arylpyridinone ITK inhibitors for treating inflammation and cancer | CONFLUENCE LIFE SCIENCES, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150210671-A1 | ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150210671-A1 | ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2015112847-A1 | ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | CONFLUENCE LIFE SCIENCES, INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| EP-1831168-B1 | PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY PROTEIN KINASES FOR THE TREATMENT OF INFLAMMATORY, PROLIFERATIVE AND IMMUNOLOGICALLY-MEDIATED DISEASES. | VERTEX PHARMA (US) | 2014-07-02 | — | — | EP | disclosed |
| US-20130184259-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184259-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| US-7786130-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1919906-A1 | 3, 5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES | Vertex Pharmaceuticals Incorporated (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1831168-A1 | PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY PROTEIN KINASES FOR THE TREATMENT OF INFLAMMATORY, PROLIFERATIVE AND IMMUNOLOGICALLY-MEDIATED DISEASES. | Vertex Pharmaceuticals Incorporated (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070179156-A1 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-20070179156-A1 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-20070179156-A1 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| WO-2007027729-A1 | 3, 5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007027729-A1 | 3, 5-DISUBSTITUTED PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY OF NON-RECEPTOR TYROSINE KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20060183911-A1 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-17 | — | — | US | disclosed |
| WO-2006065946-A1 | PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY PROTEIN KINASES FOR THE TREATMENT OF INFLAMMATORY, PROLIFERATIVE AND IMMUNOLOGICALLY-MEDIATED DISEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183911-A1 | Pyridones useful as inhibitors of kinases | MAP3K20, MAP3K6, MAP3K5 | NPC1 3807/4885RAB9A 2870/4885TACR3 3640/4885 |
| US-20150210671-A1 | ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ITK, PDXK, IRAK2 | NPC1 4121/4885RAB9A 4066/4885TACR3 2664/4885 |
| US-20150328227-A1 | ARYLPYRIDINONE ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ITK, PDXK, IRAK2 | NPC1 4121/4885RAB9A 4066/4885TACR3 2664/4885 |
| US-20070179156-A1 | Pyridones useful as inhibitors of kinases | MAP3K20, MAP3K6, MAP3K5 | NPC1 3761/4885RAB9A 2776/4885TACR3 3428/4885 |
| US-20130184259-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | MAP3K20, MAP3K6, MAP3K5 | NPC1 3807/4885RAB9A 2870/4885TACR3 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.